{"schema_version":"1.0","type":"article","title":"Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy","url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.md","lang":"en","date":"2026-07-10","publish_at":"2026-07-10T09:49:00+08:00","updated_at":"2026-07-10","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","drug development","FDA CRL","NASP","Sobi","CMC","contract manufacturing","manufacturing quality","uncontrolled gout","URAT1","clinical data","biotech investing"],"summary":"FDA identified no clinical efficacy or safety concerns that affected NASP's approvability. The setback centered on CMC controls and contract-manufacturing deficiencies, showing biotech investors why manufacturing credibility becomes part of asset value near launch.","key_points":[],"facts":[],"sections":["01｜What Is NASP? A Gout Therapy Designed to Control Uricase Immunogenicity","02｜Why Is There Still Room in This Market? Existing Therapy Remains Inconvenient and Immunogenic","03｜The FDA's Objection Was About CMC, Not Clinical Performance","04｜NASP's Progress Still Shows That High-End Gout Therapy Has Value","05｜The Biotech Investing Lesson: Do Not Evaluate the Clinic Without Evaluating the Product","06｜What Should Taiwan Investors Watch? The Urate-Lowering Chain From URAT1 to Established Drugs","Conclusion｜This CRL Exposed Manufacturing Risk at the Point Where It Matters Most"],"references":[{"title":"Sobi, [Sobi receives Complete Response Letter from FDA for NASP, nanoencapsulated sirolimus plus pegadricase](), June 26, 2026.","source":"","date":"","url":"https://www.sobi.com/en/press-releases/sobi-receives-complete-response-letter-fda-nasp-nanoencapsulated-sirolimus-plus-pegadricase-2465072"},{"title":"ClinicalTrials.gov, [DISSOLVE I, NCT04513366]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT04513366"},{"title":"ClinicalTrials.gov, [DISSOLVE II, NCT04596540]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT04596540"},{"title":"ClinicalTrials.gov, [COMPARE, NCT03905512]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT03905512"},{"title":"ClinicalTrials.gov, [AR882-301, NCT06846515]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06846515"},{"title":"ClinicalTrials.gov, [AR882-302, NCT06439602]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06439602"},{"title":"DailyMed, [KRYSTEXXA (pegloticase) injection label]().","source":"","date":"","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e566303-d93a-4130-b764-25749829aa95"},{"title":"Taiwan Food and Drug Administration, [Active drug license dataset]().","source":"","date":"","url":"https://data.gov.tw/dataset/9123"},{"title":"PubMed, [Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor]().","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/41113711/"},{"title":"PubMed, [Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs]().","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/40169562/"}],"images":[{"alt":"Figure 1 | NASP combines nanoencapsulated sirolimus with pegadricase to pair immune modulation with uric acid breakdown","url":"https://drugnews.com.tw/assets/articles/fda-nasp-en/figure-01.png"},{"alt":"Figure 2 | The NASP CRL separated clinical performance from CMC and contract-manufacturing execution","url":"https://drugnews.com.tw/assets/articles/fda-nasp-en/figure-02.png"},{"alt":"Figure 3 | NASP reached the final regulatory mile after Phase 3, but must now remediate CMC and facility issues before resubmission","url":"https://drugnews.com.tw/assets/articles/fda-nasp-en/figure-03.png"},{"alt":"Figure 4 | Gout treatment spans high-end biologics, URAT1 uricosurics, and established chronic therapies","url":"https://drugnews.com.tw/assets/articles/fda-nasp-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/fda-nasp-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-10）。Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy。https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-10-fda-nasp.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}